Sight Sciences (SGHT) Set to Announce Quarterly Earnings on Thursday

Posted by MarketBeat News on Aug 4th, 2022

Sight Sciences (NASDAQ:SGHT – Get Rating) will be posting its quarterly earnings results after the market closes on Thursday, August 11th. Analysts expect Sight Sciences to post earnings of ($0.46) per share for the quarter. Sight Sciences has set its FY 2022 guidance at EPS.Individual that wish to register for the company’s earnings conference call can do so using this link.

Sight Sciences (NASDAQ:SGHT – Get Rating) last announced its quarterly earnings results on Tuesday, May 10th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.08). Sight Sciences had a negative net margin of 134.02% and a negative return on equity of 51.67%. The business had revenue of $14.88 million during the quarter, compared to the consensus estimate of $13.60 million. On average, analysts expect Sight Sciences to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sight Sciences Stock Up 7.7 %

Shares of NASDAQ:SGHT opened at $10.03 on Thursday. The company has a current ratio of 21.28, a quick ratio of 20.94 and a debt-to-equity ratio of 0.15. Sight Sciences has a 12 month low of $6.25 and a 12 month high of $41.17. The company has a 50-day moving average price of $9.36 and a 200 day moving average price of $11.42. The company has a market cap of $477.33 million and a price-to-earnings ratio of -3.23.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Morgan Stanley lowered their price target on shares of Sight Sciences from $18.00 to $17.00 and set an “overweight” rating for the company in a report on Friday, July 15th. Stifel Nicolaus reissued an “initiates” rating on shares of Sight Sciences in a research note on Tuesday, July 26th. Finally, Piper Sandler decreased their price objective on shares of Sight Sciences from $23.00 to $17.00 in a research note on Wednesday, May 11th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Sight Sciences currently has a consensus rating of “Buy” and an average target price of $24.80.

Insider Transactions at Sight Sciences

In related news, Director Staffan Encrantz bought 300,000 shares of Sight Sciences stock in a transaction dated Monday, May 16th. The shares were acquired at an average cost of $8.20 per share, with a total value of $2,460,000.00. Following the completion of the transaction, the director now owns 301,802 shares in the company, valued at approximately $2,474,776.40. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Hedge Funds Weigh In On Sight Sciences

Institutional investors have recently bought and sold shares of the business. American International Group Inc. increased its holdings in Sight Sciences by 87.2% during the first quarter. American International Group Inc. now owns 11,088 shares of the company’s stock valued at $128,000 after buying an additional 5,165 shares during the period. Jane Street Group LLC acquired a new stake in Sight Sciences in the first quarter valued at approximately $147,000. Quantbot Technologies LP acquired a new stake in Sight Sciences in the first quarter valued at approximately $148,000. MetLife Investment Management LLC acquired a new stake in Sight Sciences in the first quarter valued at approximately $166,000. Finally, Rhumbline Advisers acquired a new stake in Sight Sciences in the first quarter valued at approximately $205,000. 60.76% of the stock is owned by hedge funds and other institutional investors.

About Sight Sciences

(Get Rating)

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists.